BioSpace News Archive

Senda Biosciences, Inc. today announced the appointment of Igor Matushansky, M.D., Ph.D., as Chief Medical Officer.

Fapon, a leading life science company, will showcase its latest innovations in in-vitro diagnostic and biopharma solutions at the 2023 American Association of Clinical Chemistry Scientific Meeting and Clinical Lab Expo from July 25 to 27.

Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Sterile Water for Injection, USP in 10mL and 20mL Single-Dose Vials.

ART MEDICAL unveiled unprecedented results on the performance of its smART+ Platform in a randomized comparative study published by the European Society for Clinical Nutrition and Metabolism’s (ESPEN’s) Clinical Nutrition.

ABVC BioPharma, Inc. announced a reverse stock split of its common stock of one post-split share for every ten pre-split shares in an effort to regain compliance with Nasdaq’s listing rules.

IPS HEART today announced the peer-reviewed publication of in vivo and in vitro study with its GIVI-MPC stem cell therapy candidate in this month’s issue of Cells (volume 12, issue 14).

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reported financial results for the half-year ended June 30, 2023 and provided a corporate update on recent developments.

MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted, novel therapeutics to improve the lives of people with brain disorders, announced the appointment of Tim Garnett, M.D. to its Board of Directors.

Kiromic BioPharma, Inc., a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the appointments of Pamela Misajon and Michael Catlin to its Board of Directors.

Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI) plans to announce its second quarter 2023 financial and operating results after the market closes on Monday, August 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.